SAS Output

21-AUG-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

64% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1558 507 33% 794 -763 832 -726
ERLYTX 76 109 143% 170 94 149 73
GI 476 111 23% 173 -302 149 -327
GU 450 521 116% 816 366 688 238
GYN 57 0 0% 0 -57 0 -57
LEUK 150 80 53% 125 -24 124 -26
LUNG 524 114 22% 178 -345 180 -344
LYMPH 172 36 21% 56 -115 49 -123
MELAN 55 120 218% 187 132 157 102
MMYEL 147 28 19% 43 -103 82 -65
OTHER 0 14   21 21 30 30
SXQOL 0 5   7 7 9 9
Total 3665 1645   2570 -1089 2449 -1216

21-AUG-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

64% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 37 364 984% 570 533 481 444
CCD 0 972   1522 1522 1532 1532
GU 0 9   14 14 9 9
LEUK 69 0 0% 0 -69 0 -69
LUNG 43 606 1409% 949 906 769 726
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 1   1 1 4 4
PREV 0 29   45 45 46 46
SURV 0 117   183 183 177 177
SXQOL 878 50 6% 78 -799 51 -827
Total 1172 2148   3362 2191 3069 1897

21-AUG-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

64% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1595 871 55% 1364 -230 1313 -282
CCD 0 972   1522 1522 1532 1532
ERLYTX 76 109 143% 170 94 149 73
GI 476 111 23% 173 -302 149 -327
GU 450 530 118% 830 380 697 247
GYN 57 0 0% 0 -57 0 -57
LEUK 219 80 37% 125 -93 124 -95
LUNG 567 720 127% 1127 560 949 382
LYMPH 225 36 16% 56 -168 49 -176
MELAN 55 120 218% 187 132 157 102
MMYEL 239 28 12% 43 -195 82 -157
OTHER 0 15   23 23 34 34
PREV 0 29   45 45 46 46
SURV 0 117   183 183 177 177
SXQOL 878 55 6% 86 -791 60 -818
Total 4837 3793   5934 1103 5518 681

21-AUG-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

64% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1012 309 31% 484 -527 521 -491
ERLYTX 76 77 101% 120 44 106 30
GI 418 63 15% 98 -319 100 -318
GU 375 376 100% 589 214 481 106
GYN 57 0 0% 0 -57 0 -57
LEUK 122 76 62% 119 -2 111 -11
LUNG 441 104 24% 162 -278 164 -277
LYMPH 129 25 19% 39 -89 36 -93
MELAN 55 92 167% 144 89 118 63
MMYEL 85 20 24% 31 -53 68 -17
OTHER 0 14   21 21 30 30
SXQOL 0 5   7 7 9 9
Total 2770 1161   1814 -950 1744 -1026

21-AUG-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

64% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 10 362 3620% 567 557 479 469
CCD 0 690   1080 1080 1138 1138
GU 0 9   14 14 9 9
LEUK 69 0 0% 0 -69 0 -69
LUNG 30 410 1367% 642 612 535 505
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 1   1 1 4 4
PREV 0 21   32 32 33 33
SURV 0 89   139 139 124 124
SXQOL 740 49 7% 76 -663 50 -690
Total 994 1631   2551 1558 2372 1378

21-AUG-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

64% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1022 671 66% 1051 29 1000 -22
CCD 0 690   1080 1080 1138 1138
ERLYTX 76 77 101% 120 44 106 30
GI 418 63 15% 98 -319 100 -318
GU 375 385 103% 603 228 490 115
GYN 57 0 0% 0 -57 0 -57
LEUK 191 76 40% 119 -71 111 -80
LUNG 471 514 109% 805 334 699 228
LYMPH 182 25 14% 39 -142 36 -146
MELAN 55 92 167% 144 89 118 63
MMYEL 177 20 11% 31 -145 68 -109
OTHER 0 15   23 23 34 34
PREV 0 21   32 32 33 33
SURV 0 89   139 139 124 124
SXQOL 740 54 7% 84 -655 59 -681
Total 3764 2792   4368 609 4116 352

21-AUG-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

64% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 65 457 703% 715 650 731 666
CCD 0 972   1522 1522 1532 1532
GI 81 15 19% 23 -57 36 -45
GU 215 429 200% 672 457 538 323
LEUK 0 38   59 59 38 38
LUNG 53 2 4% 3 -49 2 -51
LYMPH 7 0 0% 0 -7 0 -7
MELAN 0 11   17 17 14 14
MMYEL 0 7   10 10 49 49
OTHER 0 8   12 12 16 16
PREV 0 29   45 45 46 46
SURV 0 117   183 183 177 177
SXQOL 878 55 6% 86 -791 60 -818
Total 1299 2140   3347 2051 3239 1940

21-AUG-2019 6:10

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

The REPORT Procedure

Detailed and/or summarized report

Table 1

Comm. Phase Study Stat
Center
Open
Date
Months
Open
Total
Regs
Accrual
Goal
Monthly
Accrual
Rate
Date of
Expected Closure or
Temporary Closure
  BIOL SLA01 LA Gastric Ca, Immune Checkpoint Expression SWOG 02APR2019:00:00:00 4 0 400 0.0 > 15 Yrs
BREAST II NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG 13APR2017:00:00:00   7   0.2  
    S1706 Breast, Inflammatory, RT +/- Olaparib SWOG 12SEP2018:00:00:00 11 14 300 2.0 Jun-2031
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1   0.0  
  III A011106 Breast, Neoadj, ALTERNATE study ALLIANCE 15FEB2014:00:00:00   94   1.5  
    A011401 Breast, adj, Stage II/III HER2-, weight loss ALLIANCE 29AUG2016:00:00:00   251   6.7  
    A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo ALLIANCE 08DEC2016:00:00:00   117   6.5  
    B51 Breast, Regional Nodal XRT NRG 22AUG2013:00:00:00   37   0.7  
    EA1131 Brst, TNBC, Post-op Chemo vs Obs ECOG-ACRIN 20AUG2014:00:00:00   17   0.5  
    EA1151 Brst, Tomosynthesis Mammographic Screening ECOG-ACRIN 06JUL2017:00:00:00   571   41.7  
    NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG 22JAN2015:00:00:00   74   0.8  
    S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) SWOG 15NOV2016:00:00:00 33 539 1000 27.2 Dec-2020
  OTHER A221405 Breast, ET interruption, Pregnancy Outcomes ALLIANCE 15OCT2015:00:00:00   19   1.0  
CCD III A011104 Preoperative Breast MRI ALLIANCE 21FEB2014:00:00:00   22   0.5  
    A191402C PROS, Testing Decision Aids for Minority Men ALLIANCE 14JUL2017:00:00:00   19   0.3  
    S1415CD TrACER CSF Standing Order Intervention for FN SWOG 01SEP2016:00:00:00 35 3340 3960 110.5 Jan-2020
    S1703 Met Breast, STM-monitoring v Usual Care SWOG 16JUL2018:00:00:00 13 32 1320 5.0 > 15 Yrs
  OTHER ACCL16N1 Guideline Consistent Treatment AYA ALL COG 18DEC2017:00:00:00   34   0.0  
    EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer ECOG-ACRIN 17MAY2018:00:00:00   30   2.0  
    NHLBIMDS LEUK, National MDS Study ECOG-ACRIN 05APR2016:00:00:00   56   5.0  
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 06AUG2015:00:00:00   5   0.0  
    S1609 Rare Tumor, Comb Nivo/Ipi SWOG 13JAN2017:00:00:00 31 629 707 12.0 Feb-2020
  OTHER EAY131 MATCH ECOG-ACRIN 12AUG2015:00:00:00   160   3.0  
GI II EA2142 GI NEC, Adv G3, EP vs TMZ + CAP ECOG-ACRIN 06NOV2015:00:00:00   4   0.0  
    EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128 ECOG-ACRIN 01FEB2017:00:00:00   1   0.0  
    EA2165 Anal, Stg II-III, Nivolumab after CMT ECOG-ACRIN 13APR2018:00:00:00   9   1.2  
    S1613 mCRC, Adv/Met, TP vs CETIRI SWOG 09OCT2017:00:00:00 22 23 130 0.8 Apr-2030
  III A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC ALLIANCE 12SEP2017:00:00:00   17   1.2  
    A021602 PANC, Adv PNET Blinded Cabozantinib v Placebo ALLIANCE 18JUL2018:00:00:00   3   0.5  
    NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG 07NOV2017:00:00:00   9   0.7  
    S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel SWOG 03DEC2018:00:00:00 8 73 268 11.8 Dec-2020
GU II A031701 Bladder, ddGC for MIBC with DDR Tumor Alt ALLIANCE 01AUG2018:00:00:00   1   0.0  
    A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) ALLIANCE 12APR2019:00:00:00   2   0.5  
    EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) ECOG-ACRIN 08FEB2018:00:00:00   9   0.8  
    EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi ECOG-ACRIN 09JUL2018:00:00:00   9   1.2  
    NRGGU006 PROS, post-RP PSA, SRT +/- ADT w/Apalutamide NRG 27APR2018:00:00:00   2   0.3  
    S1500 pRCC,Adv, Sunitinib vs MET inhib SWOG 05APR2016:00:00:00 40 134 148 2.5 Jan-2020
  II-III NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG 30DEC2016:00:00:00   3   0.2  
  III A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) ALLIANCE 01JUL2015:00:00:00   6   0.3  
    A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs ALLIANCE 21SEP2017:00:00:00   46   3.7  
    EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT ECOG-ACRIN 08SEP2017:00:00:00   2   0.3  
    EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) ECOG-ACRIN 02FEB2017:00:00:00   50   4.2  
    NRGGU005 PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT NRG 16NOV2017:00:00:00   1   0.2  
    S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG SWOG 07FEB2017:00:00:00 30 497 969 43.5 Jun-2020
    S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum SWOG 17SEP2018:00:00:00 11 87 1273 8.7 Dec-2030
    S1806 Blad, MIBC, ChemoRT +/- Atezolizumab SWOG 19APR2019:00:00:00 4 8 475 2.0 > 15 Yrs
LEUK I-II S1318 ALL, Age 65+, Ph±, Blinatumomab SWOG 12JAN2015:00:00:00   47 44   Sep-2017 Temp Close
  II S1712 CML, Chronic Phase, TKI +/- Ruxolitinib SWOG 20JUL2018:00:00:00 13 11 84 1.3 Feb-2024
  II-III S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics SWOG 22DEC2017:00:00:00   78 1670   Oct-2018 Temp Close
  II/III A041701 AML, Age 60+, Conv Chemo +/- Uproleselan ALLIANCE 16JAN2019:00:00:00   4   0.7  
  III A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo ALLIANCE 01JUN2017:00:00:00   3   0.3  
    A041702 CLL, Stg I-IV, IO with IM versus IVO ALLIANCE 04JAN2019:00:00:00   8   1.3  
    E1910 BCR-ABL-neg, B ALL, Blinatumomab ECOG-ACRIN 23DEC2013:00:00:00   116   1.7  
    EA9161 CLL, untreated, IOV vs IO in younger pts ECOG-ACRIN 03JAN2019:00:00:00   38   6.2  
LUNG II S1400F Non-Match: MEDI4736 + Tremelimumab SWOG 02OCT2017:00:00:00   64 132   May-2019 Temp Close
    S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac SWOG 09AUG2018:00:00:00 12 2 66 0.3 > 15 Yrs
    S1800A Non-Match: Ramu + Pembro vs SoC SWOG 17MAY2019:00:00:00 3 18 144 5.7 May-2021
    S1900A LOH and/or BRCA: Rucaparib SWOG 28JAN2019:00:00:00 6 18 88 3.0 Jul-2021
  II-III NRGCC003 SCLC, PCI or HA-PCI NRG 07DEC2015:00:00:00   4   0.0  
  II/III NRGLU005 LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo NRG 28MAY2019:00:00:00   1      
  III A081105 ALCHEMIST1, EGFR mut, Erlotinib ALLIANCE 02JAN2014:00:00:00   57   1.5  
    C30610 SCLC, Thoracic RT ALLIANCE 21MAR2008:00:00:00   57   0.2  
    E4512 ALCHEMIST2, ALK mut, Crizotinib ECOG-ACRIN 18AUG2014:00:00:00   12   0.0  
    EA5142 ALCHEMIST3, Non-match, Nivolumab ECOG-ACRIN 16MAY2016:00:00:00   112   3.2  
    EA5163 NSCLC, Immunotherapy +/- 2nd line therapy ECOG-ACRIN 28FEB2019:00:00:00   6   1.0  
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 06FEB2014:00:00:00   748   14.2  
    LUNGMAP NSCLC, Adv, Master SWOG 28JAN2019:00:00:00 6 489   78.8  
  PILOT S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC SWOG 03NOV2017:00:00:00 21 17 28 1.2 May-2020
LYMPH I-II E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin ECOG-ACRIN 24JAN2014:00:00:00   4   0.7  
  II S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob SWOG 10AUG2017:00:00:00 24 31 150 2.8 Jan-2023
  III EA4151 Lymph, AHCT +/-Ritux, MRD Neg ECOG-ACRIN 29AUG2017:00:00:00   23   1.5  
    S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD SWOG 19JUL2019:00:00:00 1 0 987    
MELAN II S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) SWOG 20OCT2016:00:00:00 34 28 56 1.5 Feb-2021
    S1607 MELAN, Adv, T-VEC, MK-3475 SWOG 02OCT2017:00:00:00 22 21 64 1.7 Sep-2021
    S1616 MELAN, Adv, Ipilimumab ± Nivolumab SWOG 17JUL2017:00:00:00 25 57 94 4.5 Apr-2020
    S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab SWOG 06DEC2018:00:00:00 8 44 556 7.2 Jul-2025
  II-III EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 01MAR2016:00:00:00   36   0.0  
  III EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T ECOG-ACRIN 15DEC2015:00:00:00   41   1.3  
    EA6174 Merkel, Adjuvant Pembrolizumab vs Observation ECOG-ACRIN 23JUL2018:00:00:00   1   0.2  
MMYEL I/II A061202 MM, Poma/Dexa/Ixaz vs Poma/Dexa ALLIANCE 07FEB2014:00:00:00   1   0.2  
  II S1702 AL Amyloidosis, Relapsed, Isatuximab SWOG 08MAR2018:00:00:00 17 35 39 2.5 Sep-2019
  III S1803 MM, Maintenance, Len vs Len/Dara SWOG 27JUN2019:00:00:00 1 1 1100    
OTHER II A091401 Sarc, ALLIANCE 18JUN2015:00:00:00   10   0.0  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   16   0.7  
    EAF151 Brain, GBM, Bev, Blood Volume ECOG-ACRIN 14APR2017:00:00:00   2   0.0  
    NRGBN001 HN, novel vs. std chemoradiation + chemo NRG 28AUG2015:00:00:00   1   0.0  
    NRGGY012 End, Recurrent/Met, Ola vs Cedir vs Ola+Cedir NRG 04SEP2018:00:00:00   2   0.3  
  II-III NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG 06FEB2016:00:00:00   4   0.2  
    NRGGY009 Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev NRG 12MAY2017:00:00:00   8   0.3  
    NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG 21APR2014:00:00:00   7   0.2  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   3   0.0  
  II/III NRGHN004 HN, Adv, RT+Durvalumab vs RT+Cetuximab NRG 12DEC2017:00:00:00   1   0.2  
  III G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT NRG 12APR2010:00:00:00   1   0.0  
    N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC ALLIANCE 22SEP2009:00:00:00   8   0.2  
    R0724 Cervical, Chem+RT +/- Adj. Chemo NRG 15JAN2014:00:00:00   1   0.0  
PREV III A211102 Breast, Atypia via RPFNA, Metformin v Placebo ALLIANCE 01FEB2015:00:00:00   3   0.0  
    A211401 Lung, Varenic v Placebo, Surg Complications ALLIANCE 29SEP2017:00:00:00   4   0.7  
    A211601 Breast, Stg II-III, Aspirin ALLIANCE 01AUG2018:00:00:00   1   0.2  
    S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac SWOG 01MAR2013:00:00:00 77 250 491 3.3 Aug-2025
SURV III E1Q11 EROS: Reproductive Health in Cancer Survivors ECOG-ACRIN 30SEP2015:00:00:00   22   0.5  
    S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 23 129 817 9.2 Nov-2025
  OTHER EA9131 Leuk, Strategy to decrease early APL deaths ECOG-ACRIN 16AUG2017:00:00:00   29   1.2  
    S1316 Compar. Effectiv. Trial for MBO SWOG 09MAR2015:00:00:00 53 201 220 4.5 Dec-2019
SXQOL III A221101 Glioma, Nuvigil/Placebo Fatigue ALLIANCE 03JUN2013:00:00:00   21   0.0  
    A221505 Brst, Hypofractionated Post Mast Rad ALLIANCE 01FEB2018:00:00:00   11   0.7  
    S1600 Bladder,Radical Cystectomy Outcomes Nutrition SWOG 21FEB2019:00:00:00 6 12 200 2.0 Jun-2027
    S1614 HBV in Ca Pts, TAF vs SOC SWOG 21FEB2019:00:00:00 6 0 444 0.0 > 15 Yrs
  OTHER S1714 CIPN Risk Prediction Cohort Study, Taxanes SWOG 01MAR2019:00:00:00 5 35 1050 6.2 Mar-2033
  PILOT A221504 NSCL, Advanced, placebo vs naloxegol ALLIANCE 13OCT2017:00:00:00   4   0.3  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

21-AUG-2019 6:10

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

The REPORT Procedure

Detailed and/or summarized report

Table 1

Phase Comm. Int
grp
Stat
Center
Study NCIPROTO CA
Cntrl
Study
Temp
Close
BIOL   N   SLA01 LA Gastric Ca, Immune Checkpoint Expression   N  
OTHER BREAST Y ALLIANCE A221405 Breast, ET interruption, Pregnancy Outcomes A221405 Y  
  CCD Y COG ACCL16N1 Guideline Consistent Treatment AYA ALL ACCL16N1CD Y  
    Y ECOG-ACRIN EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer EAQ162CD Y  
    Y ECOG-ACRIN NHLBIMDS LEUK, National MDS Study NHLBI-MDS Y  
  ERLYTX Y ECOG-ACRIN EAY131 MATCH EAY131 N  
  LUNG Y SWOG LUNGMAP NSCLC, Adv, Master LUNGMAP N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  SURV Y SWOG S1316 Compar. Effectiv. Trial for MBO S1316 Y  
    Y ECOG-ACRIN EA9131 Leuk, Strategy to decrease early APL deaths EA9131 Y  
  SXQOL N   S1714 CIPN Risk Prediction Cohort Study, Taxanes   Y  
I-II LEUK Y SWOG S1318 ALL, Age 65+, Ph±, Blinatumomab S1318 N Y
  LYMPH Y ECOG-ACRIN E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin E4412 N  
II BREAST Y SWOG S1706 Breast, Inflammatory, RT +/- Olaparib S1706 N  
    Y NRG NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG-BR005 N  
  ERLYTX Y SWOG S1609 Rare Tumor, Comb Nivo/Ipi S1609 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
  GI Y SWOG S1613 mCRC, Adv/Met, TP vs CETIRI S1613 N  
    Y ECOG-ACRIN EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128 EA2161 N  
    Y ECOG-ACRIN EA2142 GI NEC, Adv G3, EP vs TMZ + CAP EA2142 N  
    Y ECOG-ACRIN EA2165 Anal, Stg II-III, Nivolumab after CMT EA2165 N  
  GU Y SWOG S1500 pRCC,Adv, Sunitinib vs MET inhib S1500 N  
    Y ECOG-ACRIN EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) EA8153 N  
    Y ECOG-ACRIN EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi EA8171 N  
    Y ALLIANCE A031701 Bladder, ddGC for MIBC with DDR Tumor Alt A031701 N  
    Y NRG NRGGU006 PROS, post-RP PSA, SRT +/- ADT w/Apalutamide NRG-GU006 N  
    Y ALLIANCE A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) A031702 N  
  LEUK Y SWOG S1712 CML, Chronic Phase, TKI +/- Ruxolitinib S1712 N  
  LUNG Y SWOG S1900A LOH and/or BRCA: Rucaparib S1900A N  
    Y SWOG S1800A Non-Match: Ramu + Pembro vs SoC S1800A N  
    Y SWOG S1400F Non-Match: MEDI4736 + Tremelimumab S1400F N Y
    Y SWOG S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac S1701 N  
  LYMPH Y SWOG S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob S1608 N  
  MELAN Y SWOG S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab S1801 N  
    Y SWOG S1607 MELAN, Adv, T-VEC, MK-3475 S1607 N  
    Y SWOG S1616 MELAN, Adv, Ipilimumab ± Nivolumab S1616 N  
    Y SWOG S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) S1512 N  
  MMYEL Y SWOG S1702 AL Amyloidosis, Relapsed, Isatuximab S1702 N  
  OTHER Y NRG NRGBN001 HN, novel vs. std chemoradiation + chemo NRG-BN001 N  
    Y ALLIANCE A091401 Sarc, A091401 N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
    Y NRG NRGGY012 End, Recurrent/Met, Ola vs Cedir vs Ola+Cedir NRG-GY012 N  
    Y ECOG-ACRIN EAF151 Brain, GBM, Bev, Blood Volume EAF151 N  
PILOT LUNG Y SWOG S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC S1619 N  
  SXQOL Y ALLIANCE A221504 NSCL, Advanced, placebo vs naloxegol A221504 Y  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N  
  GU Y NRG NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG-GU002 N  
  LEUK Y SWOG S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics S1612 N Y
  LUNG Y NRG NRGCC003 SCLC, PCI or HA-PCI NRG-CC003 Y  
  MELAN Y ECOG-ACRIN EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGGY009 Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev NRG-GY009 Y  
    Y NRG NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG-GY005 Y  
    Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG-HN001 Y  
III BREAST     EA1131 Brst, TNBC, Post-op Chemo vs Obs   N  
    Y SWOG S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) S1418 Y  
    Y ALLIANCE A011106 Breast, Neoadj, ALTERNATE study A011106 N  
    Y NRG B51 Breast, Regional Nodal XRT NSABP-B-51 Y  
    Y ALLIANCE A011401 Breast, adj, Stage II/III HER2-, weight loss A011401 Y  
    Y NRG NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG-BR003 N  
    Y ALLIANCE A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo A011502 Y  
    Y ECOG-ACRIN EA1151 Brst, Tomosynthesis Mammographic Screening EA1151 N  
  CCD Y SWOG S1415CD TrACER CSF Standing Order Intervention for FN S1415CD Y  
    Y SWOG S1703 Met Breast, STM-monitoring v Usual Care S1703 Y  
    Y ALLIANCE A011104 Preoperative Breast MRI A011104 Y  
    Y ALLIANCE A191402C PROS, Testing Decision Aids for Minority Men A191402CD Y  
  GI Y SWOG S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel S1815 N  
    Y ALLIANCE A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC A021502 Y  
    Y NRG NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG-GI004 Y  
    Y ALLIANCE A021602 PANC, Adv PNET Blinded Cabozantinib v Placebo A021602 Y  
  GU Y SWOG S1806 Blad, MIBC, ChemoRT +/- Atezolizumab S1806 Y  
    Y SWOG S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum S1802 Y  
    Y SWOG S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG S1602 Y  
    Y NRG NRGGU005 PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT NRG-GU005 Y  
    Y ECOG-ACRIN EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT EA8134 Y  
    Y ECOG-ACRIN EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) EA8143 Y  
    Y ALLIANCE A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs A031501 Y  
    Y ALLIANCE A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) A031102 Y  
  LEUK Y ECOG-ACRIN E1910 BCR-ABL-neg, B ALL, Blinatumomab E1910 N  
    Y ECOG-ACRIN EA9161 CLL, untreated, IOV vs IO in younger pts EA9161 Y  
    Y ALLIANCE A041702 CLL, Stg I-IV, IO with IM versus IVO A041702 N  
    Y ALLIANCE A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo A041501 N  
  LUNG Y ALLIANCE C30610 SCLC, Thoracic RT CALGB-30610 Y  
    Y ALLIANCE A081105 ALCHEMIST1, EGFR mut, Erlotinib A081105 N  
    Y ECOG-ACRIN EA5142 ALCHEMIST3, Non-match, Nivolumab EA5142 N  
    Y ECOG-ACRIN E4512 ALCHEMIST2, ALK mut, Crizotinib E4512 N  
    Y ECOG-ACRIN EA5163 NSCLC, Immunotherapy +/- 2nd line therapy EA5163 N  
  LYMPH Y SWOG S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD S1826 Y  
    Y ECOG-ACRIN EA4151 Lymph, AHCT +/-Ritux, MRD Neg EA4151 N  
  MELAN Y ECOG-ACRIN EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T EA6134 Y  
    Y ECOG-ACRIN EA6174 Merkel, Adjuvant Pembrolizumab vs Observation EA6174 N  
  MMYEL Y SWOG S1803 MM, Maintenance, Len vs Len/Dara S1803 N  
  OTHER Y ALLIANCE N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC N0577 N  
    Y NRG G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT GOG-0263 Y  
    Y NRG R0724 Cervical, Chem+RT +/- Adj. Chemo RTOG-0724 Y  
  PREV Y SWOG S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac S0820 Y  
    Y ALLIANCE A211401 Lung, Varenic v Placebo, Surg Complications A211401 Y  
    Y ALLIANCE A211102 Breast, Atypia via RPFNA, Metformin v Placebo A211102 Y  
    Y ALLIANCE A211601 Breast, Stg II-III, Aspirin A211601 Y  
  SURV Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y ECOG-ACRIN E1Q11 EROS: Reproductive Health in Cancer Survivors E1Q11 Y  
  SXQOL Y SWOG S1600 Bladder,Radical Cystectomy Outcomes Nutrition S1600 Y  
    Y SWOG S1614 HBV in Ca Pts, TAF vs SOC S1614 Y  
    Y ALLIANCE A221101 Glioma, Nuvigil/Placebo Fatigue A221101 Y  
    Y ALLIANCE A221505 Brst, Hypofractionated Post Mast Rad A221505 Y  
I/II MMYEL Y ALLIANCE A061202 MM, Poma/Dexa/Ixaz vs Poma/Dexa A061202 N  
II/III LEUK Y ALLIANCE A041701 AML, Age 60+, Conv Chemo +/- Uproleselan A041701 N  
  LUNG Y NRG NRGLU005 LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo NRG-LU005 Y  
  OTHER Y NRG NRGHN004 HN, Adv, RT+Durvalumab vs RT+Cetuximab NRG-HN004 Y  

21-AUG-2019 6:10

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

The REPORT Procedure

Detailed and/or summarized report

Table 1

Protocol
Number
Study Accrual
Goal
Open
Stat/Date
Months
Open
Accrual
as of
01Jan02
Current Accrual Proj.
Annual
Accr.
Rate
EXPCLOSE Proj.
Study
Duration
(Years)
S0820 S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac (PREV) 491 Y-03/01/13 77 250 250 40 Aug-2025 12.5
S1415CD S1415CD TrACER CSF Standing Order Intervention for FN (CCD) 3960 Y-09/01/16 35 3340 3340 1326 Jan-2020 3.4
S1418 S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) (BREAST) 1000 Y-11/15/16 33 539 539 326 Dec-2020 4.1
S1501 S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol (SURV) 817 Y-09/15/17 23 129 129 110 Nov-2025 8.2
S1600 S1600 Bladder,Radical Cystectomy Outcomes Nutrition (SXQOL) 200 Y-02/21/19 6 12 12 24 Jun-2027 8.3
S1602 S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG (GU) 969 Y-02/07/17 30 497 497 522 Jun-2020 3.4
S1612 S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics (LEUK) 1670 T-12/22/17 19 78 78 0 > 15 Yrs > 15 Yrs
S1614 S1614 HBV in Ca Pts, TAF vs SOC (SXQOL) 444 Y-02/21/19 6 0 0 0 > 15 Yrs > 15 Yrs
S1703 S1703 Met Breast, STM-monitoring v Usual Care (CCD) 1320 Y-07/16/18 13 32 32 60 > 15 Yrs > 15 Yrs
S1802 S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum (GU) 1273 Y-09/17/18 11 87 87 104 Dec-2030 12.3
S1803 S1803 MM, Maintenance, Len vs Len/Dara (MMYEL) 1100 Y-06/27/19 1 1 1      
S1806 S1806 Blad, MIBC, ChemoRT +/- Atezolizumab (GU) 475 Y-04/19/19 4 8 8 23.570918 > 15 Yrs > 15 Yrs
S1815 S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel (GI) 268 Y-12/03/18 8 73 73 142 Dec-2020 2.0
S1826 S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD (LYMPH) 987 Y-07/19/19 1 0 0      
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.